[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
July 3, 2002

Meetings on Drug Applications

Author Affiliations
 

Not Available

Not Available

JAMA. 2002;288(1):36. doi:10.1001/jama.288.1.36-JFD20007-4-1

The FDA's Cardiovascular and Renal Drugs Advisory Committee will hold a public meeting on July 18 at the Holiday Inn in Bethesda, Md, to consider the following applications:

(1) a proposed claim of comparative effectiveness of candesartan cilexetil and losartan in hypertension and (2) approval of pravastatin sodium/aspirin copackaged product for long-term management of cardiovascular disease. The next day the committee will consider the application for the approval of omapatrilat for treatment of hypertension. For additional information call (800) 741-8138, ext 12533.

First Page Preview View Large
First page PDF preview
First page PDF preview
×